Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
about
Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins.Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
P2860
Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Effective plasma concentration ...... e remission-maintenance phase.
@en
Effective plasma concentration ...... e remission-maintenance phase.
@nl
type
label
Effective plasma concentration ...... e remission-maintenance phase.
@en
Effective plasma concentration ...... e remission-maintenance phase.
@nl
prefLabel
Effective plasma concentration ...... e remission-maintenance phase.
@en
Effective plasma concentration ...... e remission-maintenance phase.
@nl
P2093
P2860
P1476
Effective plasma concentration ...... e remission-maintenance phase.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2710.2011.01269.X
P577
2011-04-24T00:00:00Z